
Paronychia is an inflammation of the folds of tissue surrounding the nail; proximal and/or lateral nail folds. Acute paronychia is mainly due to bacterial infection, Staphyloccus aureus or Streptococcus sometimes viral infection (herpetic whitlow). Chronic paronychia is the result of numerous conditions in which the main factor is the disappearance of the cuticle. On fingers, etiology is often a contact dermatitis; bacterial or mycological infections are secondary colonizations. Onychomycosis due to moulds (Fusarium) or dematiae (Scytalidium dimitiadum) are often associated with paronychia. Paronychia is a frequent side-effect of chemotherapies and targeted therapies. Paronychia is a common complication of lateral or proximal (retronychia) ingrown nail and systemic antibiotics are ineffective unless infection is proved. Do not use systematically systemic antibiotics.
Inflammation, Drug-Related Side Effects and Adverse Reactions, Paraneoplastic Syndromes, Neoplasms, Acute Disease, Chronic Disease, Humans, Nails, Ingrown, Paronychia, Skin Diseases
Inflammation, Drug-Related Side Effects and Adverse Reactions, Paraneoplastic Syndromes, Neoplasms, Acute Disease, Chronic Disease, Humans, Nails, Ingrown, Paronychia, Skin Diseases
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 24 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
